Background: POU1F1 is a pituitary transcription factor that plays a pivotal role in pituitary development and expression of the GH, PRL and TSH β genes. Therefore, abnormalities of the POU1F1 gene are known to be responsible for a phenotype causing combined pituitary hormone deficiency (CPHD) involving growth hormone, prolactin and thyrotropin. Methods: We described an 18-year-old Thai man, from a consanguineous family, who presented with short stature and cognitive deficit. He underwent endocrinological and molecular investigations. Results: Hormonal studies showed that the patient had GH deficiency and secondary hypothyroidism, consistent with CPHD. Direct DNA sequencing revealed a novel homozygous mutation at the splice site of exon 4, IVS4+1G>A. It is the first splice site mutation in the POU1F1 gene described to date. Of the 7 other family members studied for this mutation by restriction enzyme digestions, 5 were heterozygous. They were all unaffected, suggesting a recessive pattern of inheritance. Conclusions: We described a novel POU1F1 splice site mutation, IVS4+1G>A, the first of its kind, in a Thai patient with CPHD. Recessive inheritance is suggested. We also noted preventable morbidities which resulted from delay in diagnosis of concomitant pituitary hormone defects in newborns suspected of CPHD.

Keywords:
POU1F1, Pituitary development, Combined pituitary hormone deficiency, Secondary hypothyroidism, Growth hormone deficiency
1.
Scully KM, Rosenfeld MG: Pituitary development: regulatory codes in mammalian organogenesis. Science 2002;295:2231–2235.
2.
Cohen LE, Radovick S: Molecular basis of combined pituitary hormone deficiencies. Endocr Rev 2002;23:431–442.
3.
Dattani MT: Novel insights into the etiology and pathogenesis of hypopituitarism. Horm Res 2004;62(suppl 3):1–13.
4.
Ohta K, Nobukuni Y, Mitsubuchi H, Ohta T, Tohma T, Jinno Y, Endo F, Matsuda I: Characterization of the gene encoding human pituitary-specific transcription factor, Pit-1. Gene 1992;122:387–388.
5.
Ingraham HA, Flynn SE, Voss JW, Albert VR, Kapiloff MS, Wilson L, Rosenfeld MG: The POU-specific domain of Pit1 is essential for sequence-specific, high affinity DNA binding and DNA dependent Pit-1-Pit-1 interaction. Cell 1990;61:1021–1033.
6.
Dasen JS, Rosenfeld MG: Signaling and transcriptional mechanisms in pituitary development. Annu Rev Neurosci 2001;24:327–355.
7.
Andersen B, Rosenfeld MG: POU domain factors in the neuroendocrine system: lessons from development biology provide insights into human disease. Endocr Rev 2001;22:2–35.
8.
Li S, Crenshaw EB 3rd, Rawson EJ, Simmons DM, Swanson LW, Rosenfeld MG: Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. Nature 1990;347:528–533.
9.
Jacobson EM, Li P, Leon-del-Rio A, Rosenfeld MG, Aggarwal AK: Structure of Pit-1 POU domain bound to DNA as a dimer: unexpected arrangement and flexibility. Genes Dev 1997;11:198–212.
10.
Turton JP, Reynaud R, Mehta A, Torpiano J, Saveanu A, Woods KS, Tiulpakov A, Zdravkovic V, Hamilton J, Attard-Montalto S, Parascandalo R, Vella C, Clayton PE, Shalet S, Barton J, Brue T, Dattani MT: Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency. J Clin Endocrinol Metab 2005;90:4762–4770.
11.
Miyata I, Vallette-Kasic S, Saveanu A, Takeuchi M, Yoshikawa H, Tajima A, Tojo K, Reynaud R, Gueydan M, Enjalbert A, Tajima N, Eto Y, Brue T: Identification and functional analysis of the novel S179R POU1F1 mutation associated with combined pituitary hormone deficiency. J Clin Endocrinol Metab 2006;91:4981–4987.
12.
Rainbow LA, Rees SA, Shaikh MG, Shaw NJ, Cole T, Barrett TG, Kirk JM: Mutation analysis of POUF-1, PROP-1 and HESX-1 show low frequency of mutations in children with sporadic forms of combined pituitary hormone deficiency and septo-optic dysplasia. Clin Endocrinol (Oxf) 2005;62:163–168.
13.
McLennan K, Jeske Y, Cotterill A, Cowley D, Penfold J, Jones T, Howard N, Thomsett M, Choong C: Combined pituitary hormone deficiency in Australian children: clinical and genetic correlates. Clin Endocrinol (Oxf) 2003;58:785–794.
14.
Reynaud R, Gueydan M, Saveanu A, Vallette-Kasic S, Enjalbert A, Brue T, Barlier A: Genetic screening of combined pituitary hormone deficiency: experience in 195 patients. J Clin Endocrinol Metab 2006;91:3329–3336.
15.
Raponi M, Upadhyaya M, Baralle D: Functional splicing assay shows a pathological intronic mutation in neurofibromatosis type 1 due to intronic sequence exonization. Hum Mutat 2006;27:294–295.
16.
Pellegrini-Bouiller I, Belicar P, Barlier A, Gunz G, Charvet JP, Jaquet P, Brue T, Vialettes B, Enjalbert A: A new mutation of the gene encoding the transcription factor Pit-1 is responsible for combined pituitary hormone deficiency. J Clin Endocrinol Metab 1996;81:2790–2796.
17.
Tatsumi KI, Miyai K, Notomi T, Kaibe K, Amino N, Mizuno Y, Kohno H: Cretinism with combined hormone deficiency caused by a mutation in the Pit-1 gene. Nat Genet 1992;1:56–58.
18.
Brown MR, Parks JS, Adess ME, Rich BH, Rosenthal IM, Voss TC, Vanderheyden TC, Hurley DL: Central hypothyroidism reveals compound heterozygous mutations in the Pit-1 gene. Horm Res 1998;49:98–102.
19.
Hendriks-Stegeman BI, Augustijn KD, Bakker B, Holthuizen P, van der Vliet PC, Jansen M: Combined pituitary hormone deficiency caused by compound heterozygosity for two novel mutations in the POU domain of the Pit1/POU1F1 gene. J Clin Endocrinol Metab 2001;86:1545–1550.
20.
Salemi S, Besson A, Eble A, Gallati S, Pfaffle RW, Mullis PE: New N-terminal located mutation (Q4ter) within the POU1F1-gene (PIT-1) causes recessive combined pituitary hormone deficiency and variable phenotype. Growth Horm IGF Res 2003;13:264–268.
21.
Radovick S, Nations M, Du Y, Berg LA, Weintraub BD, Wondisford FE: A mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency. Science 1992;257:1115–1118.
22.
Radovick S, Cohen LE, Wondisfonrd FE. The molecular basis of hypopituitarism. Horm Res 1998;49 (suppl 1):30–36.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.